Peripheral glucagon-like peptide-1 (GLP-1) and satiation

Physiology and Behavior

Volumn 105, Issue 1, 2011, Pages 71-76

  Punjabi, Mukesh ^a   Arnold, Myrtha ^a   Geary, Nori ^a   Langhans, Wolfgang ^a   Pacheco López, Gustavo ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Eating; Exendin 4; Food intake; Hepatic portal vein; Hindbrain; Incretin; Meal size; Vagus

Indexed keywords

EXENDIN 9; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; ENDOCRINE FUNCTION; FOOD INTAKE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RHOMBENCEPHALON; SATIETY;

ANIMALS; EATING; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 1; RATS; RECEPTORS, GLUCAGON; RHOMBENCEPHALON; SATIATION;

EID: 80053442449     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2011.02.038     Document Type: Article

References (86)

1. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
2. Goke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995, 7:2294-2300.
3. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999, 403:261-280.
4. Kokrashvili Z., Mosinger B., Margolskee R.F. T1r3 and alpha-gustducin in gut regulate secretion of glucagon-like peptide-1. Ann NY Acad Sci 2009, 1170:91-94.
5. Shin Y.K., Martin B., Golden E., Dotson C.D., Maudsley S., Kim W., et al. Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 2008, 106:455-463.
6. Wei Y., Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996, 157:355-357.
7. Dunphy J.L., Taylor R.G., Fuller P.J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998, 141:179-186.
8. Shimizu I., Hirota M., Ohboshi C., Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987, 121:1076-1082.
9. Burcelin R., Da Costa A., Drucker D., Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001, 50:1720-1728.
10. Holst J.J. Enteroglucagon. Annu Rev Physiol 1997, 59:257-271.
11. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
12. Harkavyi A., Whitton P.S. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010, 159:495-501.
13. Holst J.J., Burcelin R., Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin. 2011.
14. Hayes M.R., De Jonghe B.C., Kanoski S.E. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 2010, 100:503-510.
15. van Dijk G., Thiele T.E., Seeley R.J., Woods S.C., Bernstein I.L. Glucagon-like peptide-1 and satiety. Nature 1997, 385:214.
16. Scott K.A., Moran T.H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007, 293:R983-R987.
17. Reidelberger R.D., Haver A.C., Apenteng B.A., Anders K.L., Steenson S.M. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obes Silver Spring 2011, 19:121-127.
18. Bradley D.P., Kulstad R., Schoeller D.A. Exenatide and weight loss. Nutrition 2010, 26:243-249.
19. Larsen P.J., Fledelius C., Knudsen L.B., Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001, 50:2530-2539.
20. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 44:81-86.
21. Gutzwiller J.P., Degen L., Heuss L., Beglinger C. Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 2004, 82:17-19.
22. Steinert R.E., Poller B., Castelli M.C., Drewe J., Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 2010, 92:810-817.
23. Choukem S.P., Gautier J.F. How do different GLP-1 mimetics differ in their actions?. Curr Diab Rep 2006, 6:365-372.
24. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.
25. Joy S.V., Rodgers P.T., Scates A.C. Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 2005, 39:110-118.
26. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
27. Rüttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
28. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
29. Hassan M., Eskilsson A., Nilsson C., Jonsson C., Jacobsson H., Refai E., et al. In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl Med Biol 1999, 26:413-420.
30. Berthoud H.R. The vagus nerve, food intake and obesity. Regul Pept 2008, 149:15-25.
31. Berthoud H.R., Neuhuber W.L. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci 2000, 85:1-17.
32. Nishizawa M., Nakabayashi H., Kawai K., Ito T., Kawakami S., Nakagawa A., et al. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 2000, 80:14-21.
33. Nakabayashi H., Nishizawa M., Nakagawa A., Takeda R., Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996, 271:E808-E813.
34. Norgren R., Smith G.P. A method for selective section of vagal afferent or efferent axons in the rat. Am J Physiol 1994, 267:R1136-R1141.
35. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991, 43:143-201.
36. Smith G.P., Jerome C., Norgren R. Afferent axons in abdominal vagus mediate satiety effect of cholecystokinin in rats. Am J Physiol 1985, 249:R638-R641.
37. Baumgartner I., Pacheco-López G., Rüttimann E.B., Arnold M., Asarian L., Langhans W., et al. Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol 2010, 22:557-563.
38. Rowland N.E., Crews E.C., Gentry R.M. Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul Pept 1997, 71:171-174.
39. Yamamoto H., Kishi T., Lee C.E., Choi B.J., Fang H., Hollenberg A.N., et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 2003, 23:2939-2946.
40. Thiele T.E., Van Dijk G., Campfield L.A., Smith F.J., Burn P., Woods S.C., et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol 1997, 272:R726-R730.
41. Seeley R.J., Blake K., Rushing P.A., Benoit S., Eng J., Woods S.C., et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000, 20:1616-1621.
42. Kinzig K.P., D'Alessio D.A., Seeley R.J. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 2002, 22:10470-10476.
43. Pacheco-López G., Punjabi M., Graber M., Geary N., Arnold M., Langhans W. Hindbrain glucagon-like peptide-1 receptors (GLP-1R) mediate the eating-inhibitory effect of hepatic portal vein (HPV) GLP-1 infusions. Society for the Study of Ingestive Behavior, Annual meeting 2010, Pittsburg, Appetite 54, 688.
44. Baraboi E.D., Smith P., Ferguson A.V., Richard D. Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am J Physiol Regul Integr Comp Physiol 2010, 298:R1098-R1110.
45. Montrose-Rafizadeh C., Avdonin P., Garant M.J., Rodgers B.D., Kole S., Yang H., et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 1999, 140:1132-1140.
46. Holz G.G.T., Leech C.A., Habener J.F. Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 1995, 270:17749-17757.
47. Sutton G.M., Patterson L.M., Berthoud H.R. Extracellular signal-regulated kinase 1/2 signaling pathway in solitary nucleus mediates cholecystokinin-induced suppression of food intake in rats. J Neurosci 2004, 24:10240-10247.
48. Sutton G.M., Duos B., Patterson L.M., Berthoud H.R. Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology 2005, 146:3739-3747.
49. Gomez E., Pritchard C., Herbert T.P. cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells. J Biol Chem 2002, 277:48146-48151.
50. D'Alessio D., Lu W., Sun W., Zheng S., Yang Q., Seeley R., et al. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am J Physiol Regul Integr Comp Physiol 2007, 293:R2163-R2169.
51. Iritani N., Sugimoto T., Fukuda H., Komiya M., Ikeda H. Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutr 1999, 129:46-50.
52. Anini Y., Fu-Cheng X., Cuber J.C., Kervran A., Chariot J., Roz C. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch 1999, 438:299-306.
53. Rüttimann E.B. Glucagon-like peptide-1 (GLP-1) and satiation [Diss, Eidgenössische Technische Hochschule ETH Zürich, Nr 18686, 2010] 2010, ETH, Zürich.
54. Shin A.C., Zheng H., Townsend R.L., Sigalet D.L., Berthoud H.R. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 2010, 151:1588-1597.
55. Beglinger C., Degen L. Gastrointestinal satiety signals in humans-physiologic roles for GLP-1 and PYY?. Physiol Behav 2006, 89:460-464.
56. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993, 138:159-166.
57. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
58. Rüttimann E.B., Arnold M., Geary N., Langhans W. GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. Physiol Behav 2010, 100:291-296.
59. Perez-Tilve D., Gonzalez-Matias L., Aulinger B.A., Alvarez-Crespo M., Gil-Lozano M., Alvarez E., et al. Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. Am J Physiol Endocrinol Metab 2010, 298:E1088-E1096.
60. Berthoud H.R., Kressel M., Raybould H.E., Neuhuber W.L. Vagal sensors in the rat duodenal mucosa: distribution and structure as revealed by in vivo DiI-tracing. Anat Embryol Berl 1995, 191:203-212.
61. Williams R.M., Berthoud H.R., Stead R.H. Vagal afferent nerve fibres contact mast cells in rat small intestinal mucosa. Neuroimmunomodulation 1997, 4:266-270.
62. Miller M.J., McDole J.R., Newberry R.D. Microanatomy of the intestinal lymphatic system. Ann NY Acad Sci 2010, 1207(Suppl. 1):E21-E28.
63. Ohtani O. Three-dimensional organization of lymphatics and its relationship to blood vessels in rat small intestine. Cell Tissue Res 1987, 248:365-374.
64. Manolas K.J., Adrian T.E., Dunlop H.M., Bacarese-Hamilton A.J., Bloom S.R., Welbourn R.B. Lymph, pancreatic and gastrointestinal hormones in response to feeding in the conscious pig. Eur Surg Res 1985, 17:324-332.
65. Tong J., Tschop M.H., Aulinger B.A., Davis H.W., Yang Q., Liu J., et al. The intestinal lymph fistula model-a novel approach to study ghrelin secretion. Am J Physiol Gastrointest Liver Physiol 2010, 298:G474-G480.
66. Bucinskaite V., Tolessa T., Pedersen J., Rydqvist B., Zerihun L., Holst J.J., et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 2009, 21:978-e78.
67. Edwards C.M., Todd J.F., Mahmoudi M., Wang Z., Wang R.M., Ghatei M.A., et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999, 48:86-93.
68. Kolligs F., Fehmann H.C., Goke R., Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995, 44:16-19.
69. Wang Z., Wang R.M., Owji A.A., Smith D.M., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 1995, 95:417-421.
70. Kim D.H., D'Alessio D.A., Woods S.C., Seeley R.J. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul Pept 2009, 155:110-114.
71. Balkan B., Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1449-R1454.
72. Guillam M.T., Hummler E., Schaerer E., Yeh J.I., Birnbaum M.J., Beermann F., et al. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet 1997, 17:327-330.
73. Burcelin R., Dolci W., Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. Diabetes 2000, 49:1643-1648.
74. Cani P.D., Holst J.J., Drucker D.J., Delzenne N.M., Thorens B., Burcelin R., et al. GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol 2007, 276:18-23.
75. Naslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999, 23:304-311.
76. Vincent R.P., Ashrafian H., le Roux C.W. Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. Nat Clin Pract Gastroenterol Hepatol 2008, 5:268-277.
77. Campbell R., Smith G. CCK-8 decreases body weight in Zucker rats. Annual meeting of Society for Neuroscience 1983, Boston, MA., USA.
78. Smith G.P., Gibbs J. The Satiety Effect of Cholecystokinin - Recent Progress and Current Problems. Ann NY Acad Sci 1985, 448:417-423.
79. Schmitz O. The GLP-1 concept in the treatment of type 2 diabetes-still standing at the gate of dawn?. J Clin Endocrinol Metab 2008, 93:375-377.
80. Roth J.D., Coffey T., Jodka C.M., Maier H., Athanacio J.R., Mack C.M., et al. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 2007, 148:6054-6061.
81. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55:3387-3393.
82. Langhans W., Zieger U., Scharrer E., Geary N. Stimulation of feeding in rats by intraperitoneal injection of antibodies to glucagon. Science 1982, 218:894-896.
83. Day J.W., Ottaway N., Patterson J.T., Gelfanov V., Smiley D., Gidda J., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009, 5:749-757.
84. Margolskee R.F., Dyer J., Kokrashvili Z., Salmon K.S., Ilegems E., Daly K., et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA 2007, 104:15075-15080.
85. Imeryuz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva-Penacarrillo M.L., Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 1997, 273:G920-G927.
86. Vahl T.P., Tauchi M., Durler T.S., Elfers E.E., Fernandes T.M., Bitner R.D., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148:4965-4973.